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administered in escalating doses to cohorts of three patients 
at each dose level. Phase II was then assessed at the selected 
maximum tolerated dose (MTD). The patients were monitored 
for acute toxicity using the Common Toxicity Criteria, version 
3.0 and late toxicity using the RTOG/EORTC.tween November 
2008 and March 2015, a total of 36 patients with primary 
carcinoma of the cervix, FIGO stage IB1 to IIIB, confirmed by 
histology, negative para-aortic lymph nodes were enrolled 
into this phase I / II trial. Chemotherapy agents were 
administered in escalating doses to cohorts of three patients 
at each dose level. Phase II was then assessed at the selected 
maximum tolerated dose (MTD). The patients were monitored 
for acute toxicity using the Common Toxicity Criteria, version 
3.0 and late toxicity using the RTOG/EORTC. 
 
Results: Of the 36 patients, 18 enrolled on phase I study. The 
MTD was confirmed to be paclitaxel 40mg/m2 and cisplatin 
40mg/m2 administered weekly for six cycles with 3D 
conformal external beam radiotherapy. There were 
additional 18 evaluable patients for the phase II 
analysis，yielding a total of 21 patients at the MTD. 3° (9/21) 
hematologic, principally neutropenia, occurs late cycles. All 
patients finished 5-6 cycles chemotherapy and radiotherapy 
in 7 weeks. The median follow-up was 24 months (5-58). At 4 
months, 18 CR (1 pCR), 3 PR. At 24 months local control rate 
was 90.4 %（19/21）. 18/21 patients (85.7％) are still survive 
( 1 was loss of follow-up). 2 of 2 recurrent or metastasis 
patients have died. Late toxicities did not appear during 
follow-up. 
 
Conclusion: Combination PTX and DDP administered 
concurrently with pelvic EBRT can be safely administered at 
the MTD of DDP 40 mg/m2 and PTX 40 mg/m2 weekly for six 
cycles in Chinese women. Primary result showed a good 
clinical outcome. We need continue follow-up. Further 
development to determine if the combination will help yield 
a survival benefit. 
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Purpose or Objective: This paper evaluates the impact of of 
FDG CT-PET in the treatment of cervical cancer by 
volumetric radiation and chemotherapy. 
 
Material and Methods: From June 2010 to October 2015, 38 
patients (pts) with cervical cancer were treated by 
radiotherapy, 21 with curatively (4 recurrences) and 17 with 
postoperatively (5 with positive margins). The mean age was 
58 years (range 32-88). The histology was: squamous cell 
carcinoma (26 pts), adenocarcinoma (9 pts), adenosquamous 
carcinoma (3 pts). The grading was: G3 in 14 pts, G2 in 23 
pts, G1 in 1 pt. The FIGO stage was: IB1 in 7 pts, IB2 in 3 pts, 
IIA1 in 5 pts, IIA2 in 2 pts, IIB in 13 pts, IIIA in 2 pts, IIIB in 2 
pts, IIIB2 in 1 pt, IIIC2 in 1 pt and IVA in 2 pts. 24 pts received 
concurrent chemotherapy (CHT), 3 neoadjuvant CHT and 1 
neoadjuvant and concomitant CHT. 3 pts were treated with 
IMRT by LINAC, 34 pts with image-guided IMRT-SB-IGRT using 
Helical Tomotherapy; 1 patient received exclusive High Dose 
Rate (HDR) brachytherapy. Tumor doses were ranged from 54 
to 70.4 Gy in 30-32 fractions (fr); dose to the pelvis were 
from 50.4 to 54 Gy / 25-30 fr. In 5 pts was treated lumbar-
aortic chain (51 Gy/30 fr); 14 pts received a boost on PET 
positive lymph nodes with dose range from 54 to 66 Gy/30 
fr). 24 pts were treated with HDR boost with dose/fraction of 
6-15 Gy in 1-3 frs. 
 
Results: 37 pts received a PET-CT to staging and planning 
(Philips GEMINI TF), 33 of these had a PET-CT evaluation post 
RT. PET –CT changed the previous stage of disease in 6/37 
cases (16%). 33 pts received also Magnetic Resonance (MRI) to 
staging, of these 10 showed positive lymph-nodes, conversely 
PET CT showed positive nodes in 20 pts (20%). 26 pts 
underwent a PET CT after RT: 18 pts showed a complete 
response (CR), 7 a partial response (PR), 1 pt a local 
persistence of lesion and a distance progression disease (PD). 
The time from end of treatment to PET evaluation was 
variable from 1 to 15 months (mean 4.3 months). About 6 pts 
with PR, 3 showed CR at the following PET-CT (8,12 and 14 
months), 1 local stable disease (SD) and distance metastases 
and 2 showed local and distance PD.  
 
Conclusion: FDG-PET changed tumor stage in 6/37 cases 
(16%) allowing a dose escalation on lymph-nodes detected 
and finally showed to be a sensitive and reliable method in 
the evaluation of radio-chemotherapy treatment response. 
The optimal timing of execution remains to be defined by 
further studies. 
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Purpose or Objective: To evaluate the toxicity and outcome 
of dose escalated radiotherapy using a simultaneous 
integrated boost (SIB) technique in patients with locally 
advanced cervical cancer at primary diagnosis or at nodal 
recurrence. 
 
Material and Methods: Sixteen patients with FIGO Stage IB2-
IIIB N1 were treated with intensity modulated radiation 
therapy utilizing a SIB technique for gross disease in the para-
aortic and/or pelvic nodal regions (8/16) or for microscopic 
disease after laparoscopic pelvic and para-aortic 
lymphadenectomy (8/16). Women were treated to 50.4 Gy in 
1.8 Gy fractions to the tumor region and the pelvic and / or 
para-aortic lymph node areas, and a simultaneous boost with 
59.36 Gy in 2.12 Gy fractions to the boost region. The boost 
volum was defined as 18FDG-PET/CT positive lymph nodes. 
Pulse-dose-rate brachytherapy was performed in eleven of 
sixteen and concurrent chemotherapy consisted of weekly 
cisplatin 40 mg/m2 in twelve patients. Acute and late 
toxicity, local control in the treated volumes, distant 
metastases and disease-free survival were assessed. 
 
Results: With a median follow-up of 22 months (range 3 -40), 
rates of acute > grade 2 gastro-intestinal (GI), genitourinary 
(GU), and hematologic toxicities were 19%, 0%, and 30%, 
respectively.There were no grade 4 acute toxicities. One 
patient developed a small bowel obstruction requiring 
surgical intervention at 16 months. The 2-year actuarial rate 
of grade ≥3 GI toxicity was 6%. There were no grade 3 or 4 
late GU or hematologic toxicities. All patients achieved 
complete remission in areas treated with high doses with SIB. 
Two patients presented a local recurrence at 6 and 30 
months of follow-up. Three cases of sixteen (19%) relapsed in 
this area when you analyzed with 18FDG-PET/CT, that 
resulted positive, but not present disease in the pathologic 
anatomy of the salvage lymphadenectomy in two of them. On 
the other hand, two of sixteen patients (12.5%) presented 
systemic disease (lung metastases) at 27 and 35 months of 
follow-up, for each patient respectively. And one patient 
presented a second neoplasm in urinary tract ten months 
after the initial treatment of the cervix neoplasm. The 2-year 
actuarial disease-free survival was 62.5% but noting that only 
one patient presented recurrence in the area of the SIB 
(6.25%).  
